Myomo Brings MyoPro to Adolescent Patients
June 06 2018 - 8:00AM
Business Wire
Myoelectric arm orthosis may help restore upper
limb functionality in teens suffering from neurological disorders
and paralysis
Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a
wearable medical robotics company, today announced that its MyoPro
myoelectric arm orthosis (powered brace) is now available to
adolescent patients with paralyzed or weakened arms. MyoPro is the
only lightweight wearable device on the market that can help
restore substantial functionality in the arms and hands of
individuals who are suffering from the effects of a neuromuscular
disease or injury.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20180606005268/en/
Zeke, 18, MyoPro User (Photo: Business
Wire)
Myomo originally developed MyoPro to assist adults suffering
from brachial plexus injury (BPI), brain or spinal cord injury,
stroke, multiple sclerosis or ALS. MyoPro is now available to help
restore upper limb functionality in adolescents with similar
neuromuscular conditions. In order to facilitate MyoPro fittings
and delivery to adolescent patients, Myomo has partnered with
Easterseals DuPage & Fox Valley (Chicago area), one of the
largest and most highly regarded pediatric outpatient
rehabilitation centers in the nation, and is exploring partnerships
with additional youth institutions and children’s hospitals that
are committed to providing innovative care to adolescents and
children with specialized needs.
Paul R. Gudonis, Chairman and CEO of Myomo, said, “For
adolescents who suffer from a neuromuscular condition like cerebral
palsy or BPI, and whose options for treatment and care have been
limited, MyoPro represents new hope. We can now provide these teens
with a chance to help restore function in their arms and, as a
result, improve their quality of life. This announcement represents
an expansion in our market reach and our ability to serve those
most in need of our technology.”
“Our partnership provides Easterseals DuPage & Fox Valley
with cutting-edge technology for our therapists and clients,” said
Kathy Schrock, vice president of clinical services, Easterseals
DuPage & Fox Valley, Illinois. “MyoPro will help develop arm
control for adolescent clients with neurological disorders, giving
them greater independence.”
Based on patented technology developed at MIT, MyoPro is a
powered brace that senses a patient’s own EMG signals through
non-invasive sensors and restores function to the paralyzed or
weakened arm. This allows MyoPro users to perform activities of
daily living including feeding themselves, carrying objects and
doing household tasks. Many adult patients are even able to return
to work.
For more information about MyoPro for adolescents, please visit
www.myomo.com/adolescents.
About MyomoMyomo, Inc. is a wearable medical robotics
company that offers expanded mobility for those suffering from
neurological disorders and upper limb paralysis. Myomo develops and
markets the MyoPro product line. MyoPro is a powered upper limb
orthosis designed to restore function to the weakened or paralyzed
arms of patients suffering from CVA stroke, brachial plexus injury,
traumatic brain or spinal cord injury, ALS or other neuromuscular
disease or injury. It is currently the only marketed device that,
sensing a patient’s own EMG signals through non-invasive sensors on
the arm, can restore an individual’s ability to perform activities
of daily living, including feeding themselves, carrying objects and
doing household tasks. Many are able to return to work, live
independently and reduce their cost of care. Myomo is headquartered
in Cambridge, Massachusetts, with sales and clinical professionals
across the U.S. For more information, please visit
www.myomo.com.
Forward Looking StatementsThis press release contains
forward-looking statements regarding the Company's future business
expectations, including the availability of MyoPro for adolescents
and potential benefits of MyoPro in increasing or restoring
function in its users, which are subject to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements are only predictions and may
differ materially from actual results due to a variety of factors.
Our actual results could differ materially from those anticipated
in these forward looking statements for many reasons, including,
without limitation, risks related to regulatory approval and market
acceptance of our products, and the other risk factors contained in
our filings made with the Securities and Exchange Commission. More
information about factors that potentially could affect Myomo's
financial results is included in Myomo's filings with the
Securities and Exchange Commission. The Company cautions readers
not to place undue reliance on any such forward-looking statements,
which speak only as of the date made. The Company disclaims any
obligation subsequently to revise any forward-looking statements to
reflect events or circumstances after the date of such statements
or to reflect the occurrence of anticipated or unanticipated
events.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180606005268/en/
For Myomo:ir@myomo.comorInvestor Relations:PCG
AdvisoryVivian Cervantes,
646-863-6274vivian@pcgadvisory.comorPublic
Relations:GreenoughRachel Robbins,
617-275-6521rrobbins@greenough.biz
Myovant Sciences (NYSE:MYOV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Myovant Sciences (NYSE:MYOV)
Historical Stock Chart
From Apr 2023 to Apr 2024